SonoClear AS has developed an acoustic coupling fluid (ACF) for use in intraoperative ultrasound for brain tumor surgery. The ACF removes noise in the ultrasound images as the acoustic properties of the fluid mimics the acoustic properties of normal brain tissue. This allows the remaining tumor to be precisely identified, providing a powerful clinical tool to achieve total removal of brain tumors and increasing the usability of intraoperative ultrasound in neurosurgery. SonoClear AS will lead the project, which will focus on the market launch and commercialization of our innovation. The main barriers for SonoClear AS going forward are related to acceptance by end-users and regulatory approval. This project will enable: 1) clinical validation and demonstration; 2) obtaining regulatory approval; 3) engaging with key opinion leaders and stakeholders. The EIC Accelerator program provides a unique opportunity for SonoClear AS to showcase the potential of its innovation and gain market intelligence that will ultimately lead to acceptance by end-users. The completion of the project objectives is important for ensuring a successful entrance to the market and commercialization of our innovative acoustic coupling fluid.
Project leader: Halvor Celius
Institution: SONOCLEAR AS